Nipro Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017
February 08, 2017
Share
Nipro Corporation reported consolidated earnings results for the nine months ended December 31, 2016. For the period, the company has reported net sales of ¥270,187 million, operating income of ¥26,148 million, ordinary income of ¥23,700 million and net income attributable to owners of parent of ¥14,071 million or ¥83.52 per basic share compared to net sales of ¥274,061 million, operating income of ¥18,431 million, ordinary income of ¥13,884 million and net income attributable to owners of parent of ¥13,968 million or ¥82.35 per basic share a year ago. Income before income taxes was ¥22,560 million against ¥12,038 million reported last year.
The company provided consolidated earnings guidance for the year ending March 31, 2017. For the year, the company expects net sales of ¥363,000 million, operating income of ¥29,000 million, ordinary income of ¥20,000 million and net income of ¥12,500 million or ¥74.44 per share.
NIPRO CORPORATION is a manufacturer of medical devices, pharmaceuticals and instrument products. The Company has three segments. The Medical-Related segment involves in the sale of injections and infusions, artificial organs, high function and dialysis related medical equipment, and diabetes, generics and kits related medicine products in Japan, as well as the sales of medical devices for injection and infusion, artificial organs and diabetes in overseas markets. The Pharmaceutical-Related segment involves in the manufacture and sale of pharmaceuticals. The Pharma Packaging segment sells glass for vials and ampoules as medical glass in Japan, thermos glass for lighting and glass for lighting equipment.
Nipro Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017
NIPRO CORPORATION 
